Swiss drugmaker Novartis has unveiled plans to construct a new radioligand therapy (RLT) manufacturing plant in Winter Park, Florida. This project is a key component of the $23 billion U.S. investment strategy previously announced by the company to bolster its supply chain for cutting-edge cancer treatments.
Optimizing the RLT supply chain The upcoming 35,000-square-foot facility is expected to become operational by 2029. This site will serve to:
-
Enhance regional access: Optimize the delivery of medicines to patients across the southeastern United States, complementing existing hubs in Indiana, New Jersey, and California.
-
Specialized manufacturing: Focus on therapies for prostate cancer and neuroendocrine tumors, fields where Novartis currently leads with FDA-approved products.
Strategic location and long-term vision Novartis selected Florida due to the state’s robust pool of specialized talent in life sciences. Expanding domestic production capabilities allows the company to navigate tariff-related challenges and address the complexities of supplying radioactive isotopes, which have short shelf lives and require stringent logistics.
To date, Novartis has pledged to build or expand 10 sites in the U.S. through 2030. This underscores its leadership in the era of precision medicine, where tumor-targeting ligands are paired with therapeutic radioisotopes to destroy cancer cells while minimizing damage to surrounding healthy tissue.